[Pilot study of Ginkgolide B, a PAF-acether specific inhibitor in the treatment of acute outbreaks of multiple sclerosis].
Ten patients with relapsing-remitting multiple sclerosis in acute relapse were treated with a five-day course of intravenous ginkgolide B, a specific inhibitor of PAF-acether. Eight patients had improvement of their neurological score, beginning 2 to 6 days after the initiation of therapy. This improvement was sustained in 5 patients and only transient in 3. Two out of these 3 patients with secondary failure and the other 2 who did not respond to ginkgolide therapy, received i.v. methylprednisolone. Three patients experienced mild side effects under ginkgolide therapy but none of the patients had any serious adverse effect. A controlled randomized study is underway, in order to confirm these results and test higher dosages and more prolonged administration.
Brochet
B
B
Clinique et Service Universitaires de Neurologie, Hôpital Pellegrin, Bordeaux, France.
Orgogozo
J M
JM
Guinot
P
P
Dartigues
J F
JF
Henry
P
P
Loiseau
P
P
D000328:Adult; D004224:Diterpenes; D005260:Female; D046934:Ginkgolides; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009460:Neurologic Examination; D010865:Pilot Projects; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*
D004224:Diterpenes; D046934:Ginkgolides; D007783:Lactones; D010972:Platelet Activating Factor; C045856:ginkgolide B
Etude pilote d'un inhibiteur spécifique du PAF-acéther, le ginkgolide B dans le traitement des poussées aiguës de sclérose en plaques.